Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TTHI's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

TTHI Guru Trades in Q4 2015

Jim Simons 236,400 sh (+15.77%)
» More
Q1 2016

TTHI Guru Trades in Q1 2016

Jim Simons 261,000 sh (+10.41%)
» More
Q2 2016

TTHI Guru Trades in Q2 2016

Jim Simons 281,400 sh (+7.82%)
» More
Q3 2016

TTHI Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TTHI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:TSX:ONC, TSXV:TBP, TSX:CXR, NAS:XENE, TSX:NEPT, TSXV:COV, TSX:TRIL, TSX:HBP, XCNQ:THC, TSXV:ABCN, OTCPK:IGXT, TSX:COM, XCNQ:CRZ, NAS:SRRA, TSXV:BTI, TSX:APS, TSXV:CZO, XCNQ:VGW, TSXV:EMH, TSXV:IPA » details
Traded in other countries:TTH.Canada, RFYA.Germany,
Headquarter Location:Canada
Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes.

Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.

Top Ranked Articles about Transition Therapeutics Inc

CEO Phillip Frost Buys OPKO Health Insider purchased 24,800 shares
Phillip Frost (Insider Trades), CEO, chairman and 10% owner of OPKO Health Inc. (NASDAQ:OPK), purchased 24,800 shares of the company on Oct. 10. The average price per share was $9.82, for a total transaction of $243,536. Read more...

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

EPS (TTM) $ -0.51
Short Percentage of Float0.47%
52-Week Range $0.66 - 2.75
Shares Outstanding (Mil)38.88

Analyst Estimate

Jun16 Jun17 Jun18 Jun19
Revenue (Mil $) 1 1 4 8
EPS ($) -0.29 -0.43 -0.43 -0.29
EPS without NRI ($) -0.29 -0.43 -0.43 -0.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TTHI

Headlines

Articles On GuruFocus.com
CEO Phillip Frost Buys OPKO Health Oct 11 2016 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}